Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort

Parkinsonism and Related Disorders

Volumn 18, Issue 6, 2012, Pages 753-758

  Wahlqvist, Mark L ^a,b,c   Lee, Meei Shyuan ^b,c   Hsu, Chih Cheng ^a,d   Chuang, Shao Yuan ^a   Lee, Jiunn Tay ^e   Tsai, Hsin Ni ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c MONASH UNIVERSITY   (Australia)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Diabetes; Metformin; Parkinson's disease; Sulfonylureas

Indexed keywords

METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG USE; ETHNIC GROUP; FEMALE; GENDER; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARKINSON DISEASE; PRIORITY JOURNAL; RISK REDUCTION; TAIWANESE;

ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PARKINSON DISEASE; RISK FACTORS; SULFONYLUREA COMPOUNDS; TAIWAN;

EID: 84862199583     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.03.010     Document Type: Article

References (30)

1. Hindle J.V. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010, 39:156-161.
2. Eggers A.E. Why do Alzheimer's disease and Parkinson's disease target the same neurons?. Med Hypotheses 2009, 72:698-700.
3. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol 2006, 5:525-535.
4. Chan D.K., Cordato D., Karr M., Ong B., Lei H., Liu J., et al. Prevalence of Parkinson's disease in Sydney. Acta Neurol Scand 2005, 111:7-11.
5. Chen C.C., Chen T.F., Hwang Y.C., Wen Y.R., Chiu Y.H., Wu C.Y., et al. Different prevalence rates of Parkinson's disease in urban and rural areas: a population-based study in Taiwan. Neuroepidemiology 2009, 33:350-357.
6. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003, 157:1015-1022.
7. Johansen K.K., Wang L., Aasly J.O., White L.R., Matson W.R., Henchcliffe C., et al. Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One 2009, 4:e7551.
8. Tanner C.M., Langston J.W. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 1990, 40(10 Suppl 3). S17-30; discussion 30-1.
9. Zheng B., Liao Z., Locascio J.J., Lesniak K.A., Roderick S.S., Watt M.L., et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010, 2(52):ra73.
10. de la Monte S.M., Wands J.R. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008, 2:1101-1113.
11. Morales R., Green K.M., Soto C. Cross currents in protein misfolding disorders: interactions and therapy. CNS Neurol Disord Drug Targets 2009, 8:363-371.
12. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100:328-341.
13. Lei P., Ayton S., Finkelstein D.I., Adlard P.A., Masters C.L., Bush A.I. Tau protein: relevance to Parkinson's disease. Int J Biochem Cell Biol 2010, 42:1775-1778.
14. Gallego M., Setien R., Izquierdo M.J., Casis O., Casis E. Diabetes-induced biochemical changes in central and peripheral catecholaminergic systems. Physiol Res 2003, 52:735-741.
15. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 1993, 69:125-130.
16. Becker C., Brobert G.P., Johansson S., Jick S.S., Meier C.R. Diabetes in patients with idiopathic Parkinson's disease. Diabetes Care 2008, 31:1808-1812.
17. Hu G., Jousilahti P., Bidel S., Antikainen R., Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007, 30:842-847.
18. Schernhammer E., Hansen J., Rugbjerg K., Wermuth L., Ritz B. Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 2011, 34:1102-1108.
19. Xu Q., Park Y., Huang X., Hollenbeck A., Blair A., Schatzkin A., et al. Diabetes and risk of Parkinson's disease. Diabetes Care 2011, 34:910-915.
20. Driver J.A., Smith A., Buring J.E., Gaziano J.M., Kurth T., Logroscino G. Prospective cohort study of Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2008, 31:2003-2005.
21. de Lau L.M., Koudstaal P.J., Hofman A., Breteler M.M. Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol 2006, 164:998-1002.
22. Simon K.C., Chen H., Schwarzschild M., Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007, 69:1688-1695.
23. Powers K.M., Smith-Weller T., Franklin G.M., Longstreth W.T., Swanson P.D., Checkoway H. Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord 2006, 12:185-189.
24. Hsu C.C., Wahlqvist M.L., Lee M.S., Tsai H.N. Incidence of dementia is increased in Type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 2011, 24:485-493.
25. Sofi F., Cesari F., Abbate R., Gensini G.F., Casini A. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 2008, 337:a1344.
26. Evatt M.L., Delong M.R., Khazai N., Rosen A., Triche S., Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 2008, 65:1348-1352.
27. Kotake Y., Ohta S. MPP+ analogs acting on mitochondria and inducing neuro-degeneration. Curr Med Chem 2003, 10:2507-2516.
28. Lee M.S., Hsu C.C., Wahlqvist M.L., Tsai H.N., Chang Y.H., Huang Y.C. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011, 11:20.
29. Levesque L.E., Hanley J.A., Kezouh A., Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010, 340:b5087.
30. Sillars B., Davis W.A., Hirsch I.B., Davis T.M. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab 2010, 12:757-765.